PDL BioPharma Inc (PDLI) Hits New 52-week Low During January 20 Session

Equities Staff  |

PDL BioPharma Inc (PDLI) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $2.95, PDL BioPharma Inc dropped to $2.87 for a new 52-week low. By the closing bell, the company's stock was at $3.03 a share for a gain of 0.17%.

Falling to a new 52-week low is never fun for company's shareholder, but, depending on who you ask, it can be either a buy or a sell signal. Someone bearish on the stock might see it reaching its lowest price in a year as a sign of growing downward momentum and make sure they sell their shares. Bulls, though, are more likely to see a new 52-week low as the stock hitting its low point and anticipate a bounce in the share price.

However one plays it, it's often a critical moment for any stock and should be noted by investors.

PDL BioPharma Inc saw 1.36 million shares of its stock trade hands, that's out of 163.58 million shares outstand. The stock has an average daily volume of 3.33 million shares. After hitting a new 52-week low, PDL BioPharma Inc enters the new trading day with a market cap of 494.82 million, a 50-day SMA of $3.61 and a 200-day SMA of $5.08

PDL BioPharma Inc now has a P/E ratio of 1.9.

For a complete fundamental analysis analysis of PDL BioPharma Inc, check out Equities.com’s Stock Valuation Analysis report for PDLI. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

PDL BioPharma Inc is engaged in the discovery of a new generation of targeted treatments for cancer & immunologic diseases. It focuses on intellectual property asset management, investing in new royalty bearing assets & maximizing value of its patent.

PDL BioPharma Inc has 10 employees, is led by CEO John P. Mclaughlin, and makes its home in Incline Villiage, NV.

PDL BioPharma Inc is also a component of the Russell 2000 Index, which is generally viewed as the most reliable indicator of the health of the broader small-cap market. Using a rules-based methodology, it creates a simple, unbiased view of how America's stable of smaller publicly traded companies are performing in the stock markets.

The index consists of the 2,000 smallest companies of the 3,000 largest publicly-traded companies in the country as judged by market cap. It's constructed by Russell Investments, which also builds and maintains the Russell 3000 (an index consisting of all 3,000 biggest companies by market cap) and the large-cap Russell 1000 (which has the 1,000 largest companies from the Russell 3000).

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer



Symbol Last Price Change % Change










World Economic Forum at Davos 2019 - Joseph Weinberg CEO PayCase, Chairman Shyft

Matt Bird sits down with Joseph Weinberg CEO PayCase, Chairman Shyft at the World Economic Forum at Davos 2019

Emerging Growth

Q BioMed Inc

Q BioMed Inc is a biomedical acceleration and development company. The company is a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences…